OncoMatch/Clinical Trials/NCT05208307
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Is NCT05208307 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Belantamab Mafodotin and Dexamethasone for plasma cell myeloma.
Treatment: Belantamab Mafodotin · Dexamethasone · Pomalidomide — This phase II trial studies the effect of belantamab mafodotin, pomalidomide, and dexamethasone in treating patents with high-risk myeloma. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as BCMA receptors, and delivers mafodotin to kill them. Chemotherapy drugs, such as pomalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving belantamab mafodotin, pomalidomide, and dexamethasone may kill more cancer cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: IGH t(14;16)
Required: IGH t(14;20)
Required: IGH t(4;14)
Required: TP53 deletion
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: autologous stem cell transplant
has undergone autologous stem cell transplant (ASCT) within one year of their diagnosis and has achieved >= partial response (PR) based on IMWG standard criteria
Cannot have received: investigational drug or approved systemic anti-myeloma therapy (including systemic steroids)
Participant must not have used an investigational drug or approved systemic anti-myeloma therapy (including systemic steroids) within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug
Cannot have received: plasmapheresis
Participant must not have had plasmapheresis within 7 days prior to first dose of study treatment
Cannot have received: monoclonal antibody
Participant must not have received prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs
Cannot have received: major surgery
Participant must not have had major surgery =< 4 weeks prior to initiating study treatment
Lab requirements
Blood counts
ANC >=1.5 x 10^9/L; Hemoglobin >= 8.0 g/dL; Platelets >= 75 x 10^9/L
Kidney function
eGFR >= 30 mL/min/1.73 m^2; Spot urine (albumin/creatinine ratios) < 500 mg/g (56 mg/mmol)
Liver function
Total bilirubin =< 1.5 x ULN (Isolated bilirubin >= 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%); ALT =< 2.5 x ULN
ANC >=1.5 x 10^9/L; Hemoglobin >= 8.0 g/dL; Platelets >= 75 x 10^9/L; Total bilirubin =< 1.5 x ULN (Isolated bilirubin >= 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%); ALT =< 2.5 x ULN; eGFR >= 30 mL/min/1.73 m^2; Spot urine (albumin/creatinine ratios) < 500 mg/g (56 mg/mmol)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University/Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify